Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

BCS
Home/The Filing Wire/iBio, Inc./ SCHEDULE 13G/A

Beneficial Ownership Report · SCHEDULE 13G/A

iBio, Inc.

IBIONASDAQEQUITYCurrent

Beneficial Ownership Report

Filed Aug 13, 2026Accepted Aug 13, 2026, 4:05 PM EDTCIK 1420720Accession 0001011438-26-000508
View company →Permanent SEC source ↗
Share

Company context

iBio (Nasdaq: IBIO) is a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, cancer, and other hard-to-treat diseases. Combining advanced antibody engineering with AI-driven discovery, iBio is advancing a differentiated pipeline designed to deliver sustained therapeutic effects and address significant unmet medical needs. iBio’s mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine.

Current securities

IBIONASDAQ · EQUITY · Current

Recent company filings

  1. Regulation FD Disclosure · Other EventsSep 14, 2026
  2. ARS filingSep 4, 2026
  3. DEF 14A filingSep 4, 2026
  4. Results of Operations and Financial ConditionAug 28, 2026
  5. 10-K filingAug 28, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.